John Valliant - Mar 30, 2022 Form 4 Insider Report for Fusion Pharmaceuticals Inc. (FUSN)

Role: Chief Executive Officer, Director
Signature: /s/Maria Stahl as Attorney-in-Fact for John Valliant
Stock symbol: FUSN
Transactions as of: Mar 30, 2022
Transactions value $: -$2,256
Form type: 4
Date filed: 4/1/2022, 05:36 PM
Previous filing: Mar 29, 2022
Next filing: Apr 5, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FUSN	Common Stock	Sale	-$2.26K	-300	-0.08%	$7.52	367K	Mar 30, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021.
F2	The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.46 to $7.65 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Content

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.46 to $7.65 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.